Spero Therapeutics Appoints Thomas Parr, Ph.D. as Chief Scientific Officer

  Spero Therapeutics Appoints Thomas Parr, Ph.D. as Chief Scientific Officer   -- Company assembles Scientific Advisory Board comprised of world-leaders in microbiology and the clinical development of anti-infectives to combat severe   infections resulting from highly drug-resistant, gram-negative bacteria --  Business Wire  CAMBRIDGE, Mass. -- May 20, 2014  Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies targeting virulence and persistence, for treatment of bacterial infections, today announced that Thomas “Tom” Parr, Ph.D. has joined the company as Chief Scientific Officer. Dr. Parr is a highly regarded microbiologist with more than 25 years of drug discovery experience across both large pharmaceutical and small biotechnology companies. The company also announced its Scientific Advisory Board (SAB). This world-renowned group of scientists brings expertise in key areas that will be invaluable in transitioning Spero’s portfolio of first-in-class anti-infectives for severe, drug-resistant infections from discovery into clinical trials.  "Tom is a talented CSO who brings to Spero substantial scientific experience in anti-infectives from discovery through commercial development," said Ankit Mahadevia, M.D., Venture Partner at Atlas Venture and Spero’s President. “As rates of bacterial resistance even to last-line antibiotics continue to rise, we look forward to Tom’s contributions to our senior management team so we may aggressively pursue the development of treatments for this evolving public health emergency.”  "We are very pleased to bring together these key thought leaders to establish the Spero Scientific Advisory Board," stated Dr. Parr. "Their deep insight in antimicrobial medicinal chemistry and in vitroandin vivo microbiology will be instrumental in advancing our therapeutic programs into clinical development. Further, the interest and direct participation of these world-class scientists on our SAB reflects the progress we're making in the discovery of new anti-infective therapies that must overcome existing drug resistance mechanisms and both limit the damage caused by the infection and promote its clearance."  Prior to joining Spero, Dr. Parr was the Chief Scientific Officer at Fedora Pharmaceuticals when the company was directing novel beta-lactamase inhibitors toward development partnerships. Earlier, he was the Chief Scientific Officer at Targanta Therapeutics, now part of The Medicines Company. While at Targanta, Dr. Parr was instrumental in progressing the lipoglycopeptide, oritavancin through to registration meetings with the FDA and EMA. Dr. Parr has worked on a broad range of marketed and experimental antibiotics including beta-lactams (cefaclor, loracarbef, cefuroxime axetil, cephalexin, moxalactam, ceftazidime, cefazolin, RWJ-333441); glycopeptides (vancomycin and oritavancin); lipodepsipeptides (daptomycin); aminoglycosides (tobramycin); quinolones (cinoxacin); macrolides (dirythromycin); and antimicrobial peptides (iseganins).  Dr. Parr earned his Ph.D. from the University of Calgary and was an MRC postdoctoral fellow at the University of British Columbia. He was an Assistant Professor in the Department of Microbiology and Biochemistry at the University of Ottawa before beginning his drug discovery and development career.  Chaired by Dr. Laurence Rahme, the members of the Spero Scientific Advisory Board include the following:    *Laurence Rahme, M.S., Ph.D., is the Spero Scientific Founder and an     Associate Professor in the Departments of Surgery, Microbiology and     Immunobiology at Harvard Medical School and Director of the Molecular     Surgical Laboratory and Associate Microbiologist in the Department of     Surgery at Massachusetts General Hospital, where she is also affiliated     with the Departments of Molecular Biology and Division of Infectious     Diseases. Dr. Rahme is internationally known for pioneering the use of P.     aeruginosa as a multi-host pathogen, the use of non-vertebrate hosts to     study P. aeruginosa-host interactions, and the development of     anti-virulence drugs that block pathogenesis but not cell viability.   *Paul Ambrose, Pharm. D. President of the Institute for Clinical     Pharmacodynamics (ICPD), Latham, New York. He is also an Honorary Research     Fellow in Infectious Diseases at the University of Oxford, Oxford, UK and     Adjunct Associate Research Professor at the University at Buffalo,     Buffalo, New York. Dr. Ambrose is an expert in anti-infective     translational science, with the goal of improving patient care through the     application of pharmacokinetic-pharmacodynamic (PK-PD) principles.   *Gordon Archer, M.D. is the Senior Associate Dean for Research and Research     Training in the Virginia Commonwealth University School of Medicine where     he directs both the M.D.-Ph.D. combined degree and the Ph.D. pre-doctoral     programs. Dr. Archer is an expert in the study of staphylococci and,     specifically antimicrobial resistance in staphylococci with a focus on     antibiotic resistance gene exchange and plasmid biology.   *George L. Drusano, M.D. is Professor of Medicine and Director, Institute     for Therapeutic Innovation of the University of Florida. He has more than     290 peer-reviewed articles and is a leader in the understanding of     mathematical modeling and pharmacodynamics for anti-infective     chemotherapy.   *Jacques Dumas, Ph.D. Chief Scientific Officer at Idenix (Cambridge,     Mass.), a public company focused on antiviral therapies, for which he     oversees all aspects of discovery and non-clinical development.     Preivously, Jacques was Vice President and Head of Strategy for Infectious     Diseases at Astrazeneca. Dr. Dumas is a medicinal chemist with expertise     in infectious disease and oncology. He is co-inventor of Nexavar and     Stivarga, two approved oncology drugs.   *Eric Gordon, PhDhas been a distinguished medicinal chemist, company     founder and senior executive since the early 1970s. He was Director of     medicinal chemistry at the Squibb Institute for Medical Research and later     Bristol-Myers Squibb, where he worked for 18 years. Since the early 1990s     Eric has participated in the building of several successful biotech     companies including Affymax, Versicor (later Vicuron Pharmaceuticals,     which was acquired by Pfizer in 2005), and Sunesis Pharmaceuticals.   *Brad Spellberg, M.D. is Professor of Medicine at the David Geffen School     of Medicine at UCLA and the Harbor-UCLA Medical Center. He is also the     Associate Medical Director for Inpatient Services and an Associate Program     Director for the Internal Medicine Residency Training Program at     Harbor-UCLA Medical Center. Dr. Spellberg is an expert in immunology,     vaccinology, and host defense against highly resistant Gram negative     bacilli, including Acinetobacter and carbapenem-resistant     Enterobacteriaceae infections.   *Glenn Tillotson, Ph.D. is a pharmaceutical industry executive with     extensive experience ranging from clinical research, to commercialization,     medical affairs, scientific communications including publication planning,     strategic drug development, life cycle management and global launch     programs. Dr. Tillotson is an expert in the development of anti-invectives     including ciprofloxacin, moxifloxacin, gemifloxacin and fidaxomicin.  About Spero  Spero is a product-focused biopharmaceutical company developing novel treatments for bacterial infections and is located in Cambridge, Massachusetts. Spero is taking a novel approach that works differently from existing antibiotics by targeting a pathway involved in two critical bacterial processes: virulence and persistence. Spero’s drug candidates may uniquely reduce the morbidity caused by severe infections and promote their clearance, including in bacterial strains highly resistant to even the most potent existing antibiotics. For more information, please visit www.sperotherapeutics.com.  Contact:  Spero Therapeutics Ankit Mahadevia, M.D. Venture Partner at Atlas Ventures or Suda Communications LLC Maureen L. Suda (Media), 585-387-9248  
Press spacebar to pause and continue. Press esc to stop.